After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

While the Chicago metropolitan area is not a major life sciences hub, a recent Cushman & Wakefield report predicts the ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.